The day Medicare officials began discussing whether to set new coverage limits on a costly new prostatecancer treatment the official in charge emailed three colleagues to put a close hold on the process That meant Keep quiet until an announcement later that month Yet by the end of that same day June   shares of the company that made the treatment Dendreon Corp had plunged  Before long federal investigators took notice